HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Stuckey, B. G.A. Articles by Deerochanawong, C. Search for Related Content PubMed PubMed Citation Articles by Stuckey, B. G.A. Articles by Deerochanawong, C. Social Bookmarking                What's this?

Sildenafil Citrate for Treatment of Erectile Dysfunction in Men With Type 1 Diabetes

Results of a randomized controlled trial

¹ Keogh Institute for Medical Research, Department of Endocrinology and Diabetes, Sir Charles Gairdner Hospital, Nedlands, Australia
² Hospital Carlos Durand, Buenos Aires, Argentina
³ Health Sciences Centre, Winnipeg, Canada
⁴ IRCCS H San Raffaele, Milan, Italy
⁵ University of Istanbul, Istanbul, Turkey
⁶ Hospital da Beneficencia, Sao Paulo, Brazil
⁷ Hospital Puerta de Hierro, Madrid, Spain
⁸ Rajavithi Hospital, Bangkok, Thailand

OBJECTIVE—In the 5–10% of diabetic men with type 1 diabetes, erectile dysfunction (ED) may be a particularly common and unwanted complication. This is the first study focusing exclusively on the effects of sildenafil in men with type 1 diabetes and ED.

RESEARCH DESIGN AND METHODS—A total of 188 patients were entered into a double-blind, placebo-controlled, parallel-group, flexible-dose study and were randomized to receive sildenafil (25–100 mg; n = 95) or placebo (n = 93) for 12 weeks. Efficacy was evaluated using questions three (Q3; achieving an erection) and four (Q4; maintaining an erection) from the International Index of Erectile Function (IIEF), a global efficacy question (GEQ; "Did treatment improve your erections?"), and a patient event log of sexual activity.

RESULTS—Improvements in mean scores from baseline to end-of-treatment for IIEF Q3 (35.7 vs. 19.9%) and Q4 (68.4 vs. 26.5%) were significant in patients receiving sildenafil compared with those receiving placebo (P = 0.0001). Moreover, the percent of improved erections (GEQ, 66.6 vs. 28.6%) and successful intercourse attempts (63 vs. 33%) was significantly increased with sildenafil compared with placebo. Improvements in sexual function were seen irrespective of the degree of ED severity. Adverse events were generally mild to moderate in severity, with headache (20 vs. 8%), flushing (18 vs. 3%), and dyspepsia (8 vs. 1%) reported more often in the sildenafil than in placebo-treated patients.

CONCLUSIONS—Treatment with sildenafil for ED was effective, resulting in an increased percentage of successful attempts at intercourse, and was well tolerated among men with type 1 diabetes.

Abbreviations: ED, erectile dysfunction • EF, erectile function • GEQ, Global Efficacy Question • IIEF, International Index of Erectile Function

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				P. J. Harwood, M. Grotz, I. Eardley, and P. V. Giannoudis Erectile dysfunction after fracture of the pelvis J Bone Joint Surg Br, March 1, 2005; 87-B(3): 281 - 290. [Full Text] [PDF]